Bristol-Myers Says Nimbus Wants To Keep New Drug For Itself
Bristol-Myers Squibb Co. and its subsidiary Celgene Corp. hit back against a biotechnology company's bid to avoid selling them a psoriasis drug the startup is developing, complaining that Nimbus Therapeutics LLC's lawsuit seeking...To view the full article, register now.
Already a subscriber? Click here to view full article